These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 31584516)
1. Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Monzo L; Ferreira JP; Abreu P; Szumski A; Böhm M; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Girerd N; Vincent J; Zannad F; Rossignol P J Hypertens; 2020 Mar; 38(3):420-425. PubMed ID: 31584516 [TBL] [Abstract][Full Text] [Related]
2. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H; Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642 [TBL] [Abstract][Full Text] [Related]
3. Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. Rossignol P; Girerd N; Gregory D; Massaro J; Konstam MA; Zannad F Int J Cardiol; 2015; 187():183-9. PubMed ID: 25828348 [TBL] [Abstract][Full Text] [Related]
4. Eplerenone in patients with systolic heart failure and mild symptoms. Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119 [TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854 [TBL] [Abstract][Full Text] [Related]
7. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240 [TBL] [Abstract][Full Text] [Related]
8. Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Ferreira JP; Lamiral Z; McMurray JJV; Swedberg K; van Veldhuisen DJ; Vincent J; Rossignol P; Pocock SJ; Pitt B; Zannad F Circ Heart Fail; 2021 Jun; 14(6):e008075. PubMed ID: 34129365 [TBL] [Abstract][Full Text] [Related]
9. Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Chin KL; Collier T; Pocock S; Pitt B; McMurray JJV; van Veldhuisen DJ; Swedberg K; Vincent J; Zannad F; Liew D Clin Res Cardiol; 2019 Jul; 108(7):806-814. PubMed ID: 30604047 [TBL] [Abstract][Full Text] [Related]
10. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130 [TBL] [Abstract][Full Text] [Related]
11. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744 [TBL] [Abstract][Full Text] [Related]
12. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Rogers JK; McMurray JJ; Pocock SJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B Circulation; 2012 Nov; 126(19):2317-23. PubMed ID: 23042980 [TBL] [Abstract][Full Text] [Related]
13. Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trials. Ferreira JP; Duarte K; Pitt B; Dickstein K; McMurray JJV; Zannad F; Rossignol P J Hypertens; 2018 Aug; 36(8):1736-1742. PubMed ID: 29683884 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
15. Blood pressure visit-to-visit variability and outcomes in patients with heart failure with preserved ejection fraction. Zhang Q; Zhou B; Ma Y; Hu Y; Li X; Cong H ESC Heart Fail; 2021 Oct; 8(5):3984-3996. PubMed ID: 34405581 [TBL] [Abstract][Full Text] [Related]
16. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681 [TBL] [Abstract][Full Text] [Related]
17. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172 [TBL] [Abstract][Full Text] [Related]
18. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624 [TBL] [Abstract][Full Text] [Related]
19. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767 [TBL] [Abstract][Full Text] [Related]
20. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial. Monzo L; Girerd N; Duarte K; Ferreira JP; McMurray JJV; van Veldhuisen DJ; Swedberg K; Pocock SJ; Pitt B; Zannad F Eur J Heart Fail; 2023 Aug; 25(8):1444-1449. PubMed ID: 37370197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]